Clinical utility of DNA methylation profiling for choroid plexus tumors
Neuro-Oncology Advances · 01.01.2024 · 6 (1)
DOI: 10.1093/noajnl/vdae097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 12.06.2024. Verfasst von Kee Kiat Yeo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Institute.
Abstract (Originalsprache)
Background
Choroid plexus tumors (CPTs) are rare, potentially aggressive CNS tumors with defined histologic criteria for grading. In recent years, several patients within our practice have demonstrated discordance between the histologic diagnosis and clinical behavior. DNA methylation profiling has emerged as a potential diagnostic adjunct for aiding the clinical approach.
Methods
We reviewed the clinical and pathologic data of all CPTs diagnosed at Boston Children’s Hospital from 1995 to 2023. All cases with available material (38/48) underwent DNA methylation profiling at NIH/NCI, and the classifier results were correlated with the WHO histologic grade and patient outcomes. Survival information was analyzed using Kaplan–Meier curves.
Results
There was good correlation (11/12, 92%) between methylation class and WHO histologic grade for choroid plexus carcinomas (CPC); one histologic CPC grouped with choroid plexus papilloma (CPP) group pediatric (P). Five CPPs grouped with methylation class CPC (5/17, 29%). In the group of atypical CPPs (n = 9), there were two that grouped with methylation class CPC. Survival analysis showed utility of methylation classes in the prediction of biologic behavior.
Conclusions
Results indicated that methylation profiling may serve as a valuable tool in the clinical decision-making process for patients with CPTs, providing additional prognostic information compared to WHO histologic grade alone. The value of methylation array analysis is particularly important given the lack of consensus on treatment regimens for CPTs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts, USA.
- Department of Pathology, Boston Children's Hospital, Boston, Massachusetts, USA.
- Department of Forensic Pathology, University of New Mexico, Albuquerque, New Mexico, USA.
- Department of Pediatrics, Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
- Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Kee Kiat Yeo, Kenneth Aldape, Sanda Alexandrescu
Förderung
- National Cancer Institute
Zitieren
APA
Yeo, K. K., Macrae, C. B., Gampel, B., Ahrendsen, J. T., Lidov, H., Wright, K. D., Chi, S., Fehnel, K., Baird, L., Clymer, J., Aldape, K., & Alexandrescu, S. (2024). Clinical utility of DNA methylation profiling for choroid plexus tumors. Neuro-Oncology Advances, 6(1). https://doi.org/10.1093/noajnl/vdae097
Vancouver
Yeo KK, Macrae CB, Gampel B, Ahrendsen JT, Lidov H, Wright KD, et al. Clinical utility of DNA methylation profiling for choroid plexus tumors. Neuro-Oncology Advances. 2024;6(1). doi:10.1093/noajnl/vdae097
BibTeX
@article{Yeo2024,
author = {Yeo, Kee Kiat and Macrae, Cassie B and Gampel, Bradley and Ahrendsen, Jared T and Lidov, Hart and Wright, Karen D and Chi, Susan and Fehnel, Katie and Baird, Lissa and Clymer, Jessica and Aldape, Kenneth and Alexandrescu, Sanda},
title = {Clinical utility of DNA methylation profiling for choroid plexus tumors},
journal = {Neuro-Oncology Advances},
year = {2024},
volume = {6},
number = {1},
doi = {10.1093/noajnl/vdae097}
}
EUVIMED